Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 3 | 2021 | 118 | 0.530 |
Why?
|
| Giant Cell Tumor of Tendon Sheath | 1 | 2016 | 1 | 0.490 |
Why?
|
| Synoviocytes | 1 | 2016 | 2 | 0.490 |
Why?
|
| Myxoma | 1 | 2016 | 4 | 0.490 |
Why?
|
| Glycoproteins | 1 | 2016 | 42 | 0.480 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 200 | 0.430 |
Why?
|
| Giant Cell Tumor of Bone | 2 | 2010 | 16 | 0.420 |
Why?
|
| Tibia | 2 | 2010 | 204 | 0.370 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 31 | 0.330 |
Why?
|
| Sarcoma | 2 | 2022 | 141 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 203 | 0.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 104 | 0.290 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 33 | 0.240 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 542 | 0.240 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 7 | 0.190 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 339 | 0.190 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 11 | 0.180 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 53 | 0.180 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 8 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 62 | 0.170 |
Why?
|
| Humans | 16 | 2022 | 23355 | 0.170 |
Why?
|
| Osteosarcoma | 1 | 2021 | 36 | 0.170 |
Why?
|
| Thymus Neoplasms | 1 | 2020 | 12 | 0.170 |
Why?
|
| Liposarcoma | 1 | 2020 | 17 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2020 | 34 | 0.160 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2019 | 3 | 0.160 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 53 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 51 | 0.150 |
Why?
|
| Pyrazoles | 2 | 2022 | 59 | 0.130 |
Why?
|
| Synovial Membrane | 1 | 2016 | 48 | 0.120 |
Why?
|
| Blotting, Western | 1 | 2016 | 133 | 0.120 |
Why?
|
| Osteitis Deformans | 1 | 2013 | 2 | 0.110 |
Why?
|
| Kyphosis | 1 | 2013 | 21 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 2013 | 5 | 0.100 |
Why?
|
| Spleen | 1 | 2013 | 29 | 0.100 |
Why?
|
| Spine | 1 | 2013 | 97 | 0.100 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 36 | 0.100 |
Why?
|
| Liver | 1 | 2013 | 142 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 240 | 0.090 |
Why?
|
| Adult | 4 | 2022 | 7078 | 0.090 |
Why?
|
| Male | 6 | 2021 | 12655 | 0.090 |
Why?
|
| Hydrazines | 1 | 2010 | 7 | 0.090 |
Why?
|
| Benzoates | 1 | 2010 | 5 | 0.090 |
Why?
|
| Curettage | 1 | 2010 | 9 | 0.080 |
Why?
|
| Vascular Neoplasms | 1 | 2010 | 4 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2010 | 9 | 0.080 |
Why?
|
| Thoracoscopy | 1 | 2010 | 22 | 0.080 |
Why?
|
| Blood Vessels | 1 | 2010 | 14 | 0.080 |
Why?
|
| Patellar Ligament | 1 | 2010 | 35 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 82 | 0.080 |
Why?
|
| Bone Cements | 1 | 2010 | 82 | 0.080 |
Why?
|
| Middle Aged | 6 | 2021 | 8072 | 0.080 |
Why?
|
| Biopsy | 1 | 2010 | 193 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2022 | 3040 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2013 | 2989 | 0.080 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 8 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2010 | 177 | 0.070 |
Why?
|
| Female | 7 | 2021 | 13149 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 593 | 0.070 |
Why?
|
| Reoperation | 1 | 2010 | 776 | 0.060 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2010 | 588 | 0.050 |
Why?
|
| Pyrroles | 1 | 2022 | 23 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 26 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 44 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2022 | 29 | 0.050 |
Why?
|
| Young Adult | 2 | 2021 | 1676 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 53 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 89 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2020 | 3 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 87 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 171 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 36 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 28 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2020 | 33 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 274 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 323 | 0.040 |
Why?
|
| Pyrazines | 1 | 2019 | 12 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 29 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 200 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 272 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 146 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 740 | 0.040 |
Why?
|
| Time Factors | 1 | 2022 | 1290 | 0.040 |
Why?
|
| Child | 1 | 2021 | 1171 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 1917 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2013 | 8 | 0.030 |
Why?
|
| Cytarabine | 1 | 2013 | 11 | 0.020 |
Why?
|
| Etoposide | 1 | 2013 | 27 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2013 | 18 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 98 | 0.020 |
Why?
|
| Cisplatin | 1 | 2013 | 60 | 0.020 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2010 | 2 | 0.020 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2010 | 2 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2010 | 3 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 2010 | 5 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2010 | 24 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2010 | 35 | 0.020 |
Why?
|
| Ilium | 1 | 2010 | 28 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 89 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2013 | 274 | 0.020 |
Why?
|
| Arthralgia | 1 | 2010 | 95 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 880 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 51 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 3785 | 0.010 |
Why?
|
| Aged | 1 | 2010 | 7562 | 0.010 |
Why?
|